Across TCGA pan-cancer cohorts, SIRT7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SIRT7 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SIRT7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SIRT7 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where SIRT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.226	0.844	<.001	37	view →
LSCC	DFS	Median	All	0.506	0.990	.018	2	view →
LUAD	OS	Tertile	All	1.000	0.933	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: SIRT7 tumor-vs-normal RNA expression · all SIRT7 data types